Is CRISPR Therapeutics Stock a Good Buy Now, or Is It Too Late?
In mid-June, the gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) released new and highly positive data from two small clinical trials of its CTX001 gene-editing therapy for beta thalassemia and sickle cell disease. After reporting these preliminary results, CRISPR's stock jumped, leaving it more than 40% above its price at the start of the year. Now investors are wondering if the stock will continue to expand.
In my view, the stock's substantial growth this year is a bit of an overreaction by the market. The company is still nowhere near obtaining regulatory approval to sell any of its therapies, and the scope of the recent clinical update was quite small. Nonetheless, I think it's entirely possible that people who buy CRISPR stock right now will be rewarded heartily over the next few years. In short, with this new data, the company has another key ingredient it needs to build a brand as a leading gene therapy company: emotionally moving success stories from its patients.
Image source: Getty Images.
Source Fool.com
